Evidence map›Paper›PMID 37592084›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2023

Clinical impact of Prostate-Specific Membrane Antigen Positron Emission Tomography (PET) on intensification or deintensification of advanced renal cell carcinoma management.

Shivanshan Pathmanathan, Arsalan Tariq, Adam Pearce, Handoo Rhee, Samuel Kyle, Sheliyan Raveenthiran, David Wong, Rhiannon McBean, Phillip Marsh, Steven Goodman and 10 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
1.8field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 7 citations in OpenAlex.

  1. High Prognostic Value ofDiagnostics (Basel, Switzerland) · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 4 institutions in 1 country.

Shivanshan PathmanathanDepartment of Medical Oncology, Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia.
Arsalan TariqDepartment of Urology, Royal Brisbane and Women's Hospital, Brisbane, Queensland, 4029, Australia.
Adam PearceDepartment of Urology, Royal Brisbane and Women's Hospital, Brisbane, Queensland, 4029, Australia.
Handoo RheeFaculty of Medicine, The University of Queensland, Brisbane, Queensland, Australia.
Samuel KyleDepartment of, Medical Imaging, Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia.
Sheliyan RaveenthiranDepartment of Urology, Royal Brisbane and Women's Hospital, Brisbane, Queensland, 4029, Australia.
David WongI-MED Radiology, The Wesley Hospital, Brisbane, Queensland, Australia.
Rhiannon McBeanI-MED Radiology, The Wesley Hospital, Brisbane, Queensland, Australia.
Phillip MarshDepartment of Diagnostic Radiology, Princess Alexandra Hospital, Brisbane, Queensland, Australia.
Steven GoodmanDepartment of Nuclear Medicine, Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia.
Nattakorn DhiantravanDepartment of Nuclear Medicine, Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia.
Rachel EslerDepartment of Urology, Royal Brisbane and Women's Hospital, Brisbane, Queensland, 4029, Australia.
Nigel DunglisonDepartment of Urology, Royal Brisbane and Women's Hospital, Brisbane, Queensland, 4029, Australia.
Anojan NavaratnamDepartment of Urology, Royal Brisbane and Women's Hospital, Brisbane, Queensland, 4029, Australia.
John YaxleyDepartment of Urology, Royal Brisbane and Women's Hospital, Brisbane, Queensland, 4029, Australia.
Paul ThomasFaculty of Medicine, The University of Queensland, Brisbane, Queensland, Australia.
David A PattisonFaculty of Medicine, The University of Queensland, Brisbane, Queensland, Australia.
Jeffrey C GohDepartment of Medical Oncology, Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia.
Chun Loo GanDepartment of Medical Oncology, Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia.
Matthew J RobertsDepartment of Urology, Royal Brisbane and Women's Hospital, Brisbane, Queensland, 4029, Australia. m.roberts2@uq.edu.au.ORCID 0000-0003-0552-7402
The University of Queensland · AURoyal Brisbane and Women's Hospital · AUWesley Hospital · AUPrincess Alexandra Hospital · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThere is an emerging role of the use of Prostate-Specific Membrane Antigen (PSMA) Positron Emission Tomography (PET) in renal cell carcinoma. Herein, we report our experience in use of PSMA PET in recurrent or metastatic renal cell carcinoma (RCC).

methodsA retrospective analysis of all patients who underwent PSMA PET for suspected recurrent or de-novo metastatic RCC between 2015 and 2020 at three institutions was performed. The primary outcome was change in management (intensification or de-intensification) following PSMA PET scan. Secondary outcomes included histopathological correlation of PSMA avid sites, comparison of sites of disease on PSMA PET to diagnostic CT and time to systemic treatment.

results

Indexed as

Carcinoma, Renal CellKidney NeoplasmsProstatic NeoplasmsGallium RadioisotopesHumansMalePositron-Emission TomographyPositron Emission Tomography Computed TomographyProstateProstate-Specific AntigenRetrospective StudiesGallium RadioisotopesProstate-Specific AntigenManagementPositron emission tomographyProstate specific membrane antigenRenal cell carcinomaStaging

Identifiers

PMID37592084
PMCPMC10684606
OpenAlexW4385968724

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.